Parnell Pharmaceuticals Holdings Ltd
Parnell Pharmaceuticals Holdings Ltd, a commercial-stage pharmaceutical company, focuses on developing, manufacturing, and marketing animal pharmaceutical products worldwide. The company operates through four segments: Companion Animal, Production Animal - U.S., Production Animal - Rest of World, and Manufacturing Operations. It markets various products, including estroPLAN and GONAbreed reproduc… Read more
Parnell Pharmaceuticals Holdings Ltd (PARNF) - Total Liabilities
Latest total liabilities as of September 2019: $0.00 USD
Based on the latest financial reports, Parnell Pharmaceuticals Holdings Ltd (PARNF) has total liabilities worth $0.00 USD as of September 2019.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Parnell Pharmaceuticals Holdings Ltd - Total Liabilities Trend (2011–2021)
This chart illustrates how Parnell Pharmaceuticals Holdings Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Parnell Pharmaceuticals Holdings Ltd Competitors by Total Liabilities
The table below lists competitors of Parnell Pharmaceuticals Holdings Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sakana SA
WAR:SKN
|
Poland | zł3.60 Million |
|
Mobilityone Ltd
LSE:MBO
|
UK | GBX16.47 Million |
|
GREAT WORLD CO HLDG
BE:TTQ
|
Germany | €207.43 Million |
|
BJNS -H- (BJ3.SG)
STU:BJ3
|
Germany | €38.49 Billion |
|
MING FAI INTERNATIO
BE:36Y
|
Germany | €772.01 Million |
Liability Composition Analysis (2011–2021)
This chart breaks down Parnell Pharmaceuticals Holdings Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.41 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | N/A | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | N/A | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Parnell Pharmaceuticals Holdings Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Parnell Pharmaceuticals Holdings Ltd (2011–2021)
The table below shows the annual total liabilities of Parnell Pharmaceuticals Holdings Ltd from 2011 to 2021.
| Year | Total Liabilities | Change |
|---|---|---|
| 2021-12-31 | $74.90 Million | +3.40% |
| 2020-12-31 | $72.43 Million | +10.99% |
| 2019-12-31 | $65.26 Million | +25.47% |
| 2018-12-31 | $52.01 Million | +25.27% |
| 2017-12-31 | $41.52 Million | +5.08% |
| 2016-12-31 | $39.51 Million | +52.25% |
| 2015-12-31 | $25.95 Million | +81.16% |
| 2014-12-31 | $14.33 Million | -50.89% |
| 2013-12-31 | $29.17 Million | 0.00% |
| 2012-12-31 | $29.17 Million | +45.13% |
| 2011-12-31 | $20.10 Million | -- |